Semaglutide vs Orforglipron
How Semaglutide and Orforglipron differ on mechanism, dosing, and the strength of the evidence behind each.
How this is graded
Every compound below carries a REGEN research grade, from S (regulatory approval behind the use it is bought for) down to F (no clinical evidence). Ordering follows that grade rather than search volume, so the compound at the top is the one with the most evidence, not the one most often sold. Doses are those reported in published protocols and are not recommendations.
Semaglutide
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that slows gastric emptying, increases satiety, and improves insulin sensitivity and glucose control. Originally developed for type 2 diabetes, it has become a leading weight-loss therapy. Dosing is titrated up slowly over weeks to minimize gastrointestinal side effects like nausea. It directly affects metabolic markers — expect improvements in HbA1c, fasting glucose, and body composition. Not typically stacked with growth or healing peptides; used as a standalone metabolic tool.
Orforglipron
Orforglipron is a fundamentally different kind of GLP-1 medicine: a small-molecule, non-peptide oral GLP-1 receptor agonist, taken as a once-daily tablet at any time of day, with or without food — unlike semaglutide's oral form (Rybelsus), which must be taken fasted with a small sip of water and a 30-minute food/drink delay. Developed by Eli Lilly under the development code LY3502970, orforglipron received FDA approval on April 1, 2026 under the brand name Foundayo, for adults with obesity or overweight with a weight-related medical problem. Its inclusion here alongside injectable peptides mirrors how MK-677 — also a non-peptide, orally active compound — sits in REGEN's catalog as a notable exception to the peptide-only norm.
Evidence compared
| Semaglutide | Orforglipron | |
|---|---|---|
| Research grade | Sgrade | Sgrade |
| Reported dose | 0.25–2.4 mg | 0.8–17.2 mg |
| Frequency | 1x weekly (titrated) | 1x daily (titrated) |
| Half-life | ~7 days | ~29–49 hours (once-daily oral dosing) |
| Routes | subcutaneous, oral | oral |
| Tracked outcomes | Weight Loss, Immune Function, Body Composition, Muscle Growth, Cognitive Function | — |
| Contraindications | personal/family history of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy | personal/family history of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy |
Which has more behind it
Semaglutide and Orforglipron sit at the same research grade (S), so the choice between them turns on mechanism and tolerability rather than evidence weight. Both entries link through to the full reference, where the trial list and citations for each claim are set out in full.
Full Semaglutide reference · Full Orforglipron reference
At a glance
| Compound | Grade | Reported dose | Half-life |
|---|---|---|---|
| Semaglutide | Sgrade | 0.25–2.4 mg · 1x weekly (titrated) | ~7 days |
| Orforglipron | Sgrade | 0.8–17.2 mg · 1x daily (titrated) | ~29–49 hours (once-daily oral dosing) |
Frequently asked questions
Semaglutide or Orforglipron, which has better evidence?
Semaglutide and Orforglipron sit at the same research grade (S), so the choice between them turns on mechanism and tolerability rather than evidence weight.
Can Semaglutide and Orforglipron be used together?
The catalog does not list Semaglutide and Orforglipron as a common pairing. Combining compounds does not combine their evidence.
What doses are reported for Semaglutide?
Published protocols report 0.25–2.4 mg, 1x weekly (titrated). This is what the literature describes, not a recommendation.
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity · Wilding JPH, et al. · 2021
- FDA Approval Announcement for Wegovy (2021). · 2021
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. · Lincoff AM, Brown-Frandsen K, Colhoun HM et al. · 2023
- Semaglutide, a glucagon like peptide-1 receptor agonist with ... - NIH · Mahapatra MK, Karuppasamy M, Sahoo BM · 2022
- Semaglutide Mechanism of Action Review. PMC. · Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A · 2022
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. · McGuire DK, Marx N, Mulvagh SL et al. · 2025
- Semaglutide | C187H291N45O59 | CID 56843331 - PubChem - NIH
- Central Nervous System Effects of GLP-1 Agonists. Nature Medicine.
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. · McGuire DK, Busui RP, Deanfield J et al. · 2023
- Semaglutide - StatPearls - NCBI Bookshelf
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021. · Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MT, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF · 2021
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. · Perkovic V, Tuttle KR, Rossing P et al. · 2024
- Molecular mechanisms of semaglutide and liraglutide as a ... · Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramírez P, Paz-Cruz E, Zambrano-Villacres R, Simancas-Racines D, Zambrano AK · 2024